Sun Pharmaceutical Industries Ltd. closed 13.60% short of its 52-week high of 1,960.20 rupees, which the company achieved on ...

By Kashish Tandon and Rishika Sadam HYDERABAD/BENGALURU (Reuters) -Sun Pharmaceutical, India's largest drugmaker by revenue, ...

Results: Sun Pharmaceutical Industries on Friday said its consolidated net profit increased 15 per cent on-year to Rs 2,903 ...

Net Sales at Rs 13,675.46 crore in December 2024 up 10.46% from Rs. 12,380.70 crore in December 2023. Quarterly Net Profit at ...

Sun Pharmaceutical Industries reported a 15% rise in net profit for the December quarter, driven by strong global sales. The ...

Sun Pharma's US formulation sales stood at $474 million during the quarter, which was lower than the expectations of $516 ...

The drug major will appeal against the order. Shares of Sun Pharmaceutical Industries Ltd ended at ₹1,762.90, up by ₹22.95, ...

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue ...

Revenue from operations grew 10.5% yoy to ₹13,675.4 crore, compared with ₹12,381 crore registered for the same period in Q3 ...

Sun Pharmaceutical Industries Ltd. reported consolidated net profit rose 15% to ₹2,903 crore for the third quarter ended December 31, 2024 from ₹2,524 crore a year earlier. Gross sales during the ...

Sun Pharmaceutical Industries Ltd. closed 9.85% below its 52-week high of 1,960.20 rupees, which the company reached on ...

Sales in India, Sun Pharma's largest revenue-generating region, rose 14% to 43 billion rupees, or about 31% of total sales. That was bigger than the 11% increase in the previous quarter.